Replicate Bioscience

Executive Summary

Replicate Bioscience is a clinical-stage biotechnology company pioneering self-replicating RNA (srRNA) technology to enable durable and potent protein expression for a wide range of diseases, including infectious diseases, oncology, and autoimmune disorders. Founded in 2019 and based in San Diego, the company's platform amplifies protein expression within cells, offering advantages over conventional linear mRNA in terms of magnitude and duration of therapeutic effect. With its srRNA technology, Replicate aims to address key limitations of current RNA therapeutics and vaccines, potentially leading to fewer doses and stronger immune responses. The company is advancing multiple programs, though specific pipeline details remain undisclosed, positioning itself as a versatile player in the RNA therapeutics space.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for lead srRNA vaccine candidate60% success
• Q4 2026Strategic partnership or licensing deal for srRNA platform50% success
• Q1 2027IND filing for first oncology program using srRNA45% success